Insider Trading disclosures for Zenas Biopharma Inc.
The latest disclosure was made by Leon Moulder O. in Zenas Biopharma Inc. where a trade of 25,000
Common Stock done at an average price of $6.7
was reported to US exchanges on Feb. 18, 2025.
Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Client Name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Traded % |
Avg. Price |
Value |
Security Type |
|
Leon Moulder O.
|
Director, Chief Executive Officer |
Purchase of securities on an exchange or from another person at price $ 6.67 per share. |
18 Feb 2025 |
25,000 |
266,155
|
-
|
6.7 |
166,750
|
Common Stock |
|
Ting Xiao
|
Director |
Purchase of securities on an exchange or from another person at price $ 7.76 per share. |
07 Feb 2025 |
10,000 |
47,000
|
-
|
7.8 |
77,600
|
Common Stock |
|
Ting Xiao
|
Director |
Purchase of securities on an exchange or from another person at price $ 7.76 per share. |
07 Feb 2025 |
10,000 |
10,000
|
-
|
7.8 |
77,600
|
Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges